PFIZER2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member PFIZER2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares PFIZER 2019-04-01 2020-03-31 2020-06-05 INR Crores Yearly Single segment Pharmaceuticals 2020-01-01 2020-03-31 Audited Standalone 5020100000.00 452200000.00 5472300000.00 902200000.00 1982800000.00 -973500000.00 1006500000.00 36200000.00 284100000.00 1015000000.00 4253300000.00 1219000000.00 0.00 1219000000.00 -120700000.00 309600000.00 188900000.00 0.00 1030100000.00 0.00 0.00 0.00 0.00 1030100000.00 -51900000.00 978200000.00 0.00 0.00 457500000.00 10 22.52 22.52 0.00 0.00 22.52 22.52 NOTES: n n1. The Company elected to exercise the option permitted under Section 115BAA of the Income Tax Act, n1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company nhas recognized Provision for Income Tax for the year ended 31 March 2020 and remeasured its ndeferred tax assets and deferred tax liabilities basis the rate prescribed in the said section. The full nimpact of this change has been recognized in the Statement of Profit and Loss. n n2. During the year, the Company divested rights and interests in two brands for a consideration of nRs 37 crore. The income of Rs 31 crore (31 March 2019: Rs 29 crore), net of related expenses and ndeferment of revenue as per Ind AS 115 on account of supply arrangement, is included in n‘Other Income’. n n3. The Board of Directors at its Meeting held on 27 April 2020 declared a special (interim) dividend of nRs 320 per equity share of Rs 10 each (3200%) for the financial year ended 31 March 2020. This being nan event after the reporting date, in accordance with Ind AS 10, no adjustments have been made in nthe financial statements for the year ended 31 March 2020. n nIn addition to the above, the Board of Directors had further at its Meeting held today, recommended na final dividend of Rs 10 per equity share of Rs 10 each (100%) for the financial year ended 31 March n2020. n n4. COVID-19, a pandemic caused by the novel Coronavirus, has emerged as an unprecedented nchallenge globally and to the pharmaceutical companies in particular, who have a responsibility ntowards public health. As a participant in this eco-system, the Company has taken a number of steps nto respond to this unique situation. The Company has taken effective steps to ensure supply of nessential medicines to its customers. The Company’s Goa Plant continues to remain operational at nalmost its usual capacity. The Company has strictly followed the protocols on social distancing and nprovided safe working environment at its Goa Plant. n nThe Company transitioned into a full Work From Home model and several measures were put in nplace for communications, technology and productivity improvements to help employees cope with nthis change. The Company also made various contributions to Government, health department, npublic healthcare workers, etc., as part of its COVID-19 CSR initiatives. nThere has been no significant adverse operational impact on the Company’s supply chain during nMarch 2020 due to the Nationwide lockdown imposed by the Government of India in view of nCOVID-19, a pandemic caused by the Novel Coronavirus. The Company has monitored the impact of nCOVID-19 on all aspects of its business. The management has exercised due care, in concluding on nsignificant accounting judgements and estimates, recoverability of receivables, assessment for nimpairment of goodwill, intangible assets, inventory based on the information available as on date, nwhile preparing the financial results as of and for the year ended 31 March 2020. n nIn view of the continued uncertainties and its inability to predict the extend and duration of nCOVID-19 situation, the Company currently is unable to predict any future impact on its business noperations. The Company will continue to ensure supply of essential medicines and take steps to nmitigate any risks associated with COVID-19 pandemic. n n5. The current tax for quarter and year ended March 31, 2020 includes reversal of Rs. 44.5 Crore pertaining to prior years’ income tax provisions. Single segment 2019-04-01 2020-03-31 Audited Standalone 21516500000.00 1840200000.00 23356700000.00 3452100000.00 4838100000.00 -366200000.00 3645100000.00 108500000.00 1032400000.00 4221800000.00 16931800000.00 6424900000.00 0.00 6424900000.00 1332000000.00 1600000.00 1333600000.00 0.00 5091300000.00 0.00 0.00 0.00 0.00 5091300000.00 -89300000.00 5002000000.00 0.00 0.00 457500000.00 10 33497400000.00 111.28 111.28 0.00 0.00 111.28 111.28 Other Expenses 1015000000.00 Other Expenses 4221800000.00